5 results about "Caspase activity" patented technology

Embodiments are directed towards methods of inducing caspase activity. The methods include contacting a cell with a treatment compound represented by the following Formula (I): where R1 is selected from hydrogen or an alkyl group having from 1 to about 16 carbon atoms; R2 is selected from a hydroxyl group, a tosylate group, an alkoxy group of the formula OR3 where R3 is selected from an alkyl group having from 1 to about 16 carbon atoms, or an ester group of the formula OCOR4, where R4 is an alkyl group having from 1 to about 16 carbon atoms, and n is from 4 to 46,000, with the proviso that when R1 is hydrogen and R2 is a hydroxy group the treatment compound has a number average molecular weight from 10,100 to 2,000,0000 g / mol.

A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3 / 7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.

This disclosure concerns the treatment of wounds. Disclosed herein are compositions and methods for treating wounds, in particular chronic wounds, using caspase-3 inhibitors. Also disclosed are methods of detecting wounds based on levels of cleaved caspase-3 and / or caspase-3 activity in a wound sample.

A method for treating or reducing the severity of neurodevelopmental defects in a developing nervous system after exposure to an anesthetic by modulating or inhibiting caspase activity, for example, by administering a pan-caspase inhibitor such as pan-caspase inhibitor Q-VD-OPh to a subject having or at risk of congestive heart disease and / or having a ciliopathic disorder.

To provide methods of inducing caspase activity.SOLUTION: The method comprises contacting a cell with a treatment compound formed by alkoxylation of an initiator using an oxide. The treatment compound is exemplified by Formula III below. In the formula, n is independently 1 to 303.SELECTED DRAWING: None